Clinical characteristics and treatment propensity in elderly patients aged over 80 years with colorectal cancer
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Elderly patients (≥ 80 years) with colorectal cancer (CRC) tend to avoid active treatment at the time of diagnosis despite of recent advances in treatment. The aim of this study was to determine treatment propensity of elderly patients aged ≥ 80 years with CRC in clinical practice and the impact of anticancer treatment on overall survival (OS). Methods: Medical charts of 152 elderly patients (aged ≥ 80 years) diagnosed with CRC between 1998 and 2012 were retrospectively reviewed. Patients’ clinical characteristics, treatment modalities received, and clinical outcome were analyzed. Results: Their median age was 82 years (range, 80 to 98). Of 152 patients, 148 were assessable for the extent of the disease. Eighty-two of 98 patients with localized disease and 28 of 50 patients with metastatic disease had received surgery or chemotherapy or both. Surgery was performed in 79 of 98 patients with localized disease and 15 of 50 patients with metastatic disease. Chemotherapy was administered in only 24 of 50 patients with metastatic disease. Patients who received anticancer treatment according to disease extent showed significantly longer OS compared to untreated patients (localized disease, 76.2 months vs. 15.4 months, p = 0.000; metastatic disease, 9.9 months vs. 2.6 months, p = 0.001). Along with anticancer treatment, favorable performance status (PS) was associated with longer OS in multivariate analysis of clinical outcome. Conclusions: Elderly patients aged ≥ 80 years with CRC tended to receive less treatment for metastatic disease. Nevertheless, anticancer treatment in patients with favorable PS was effective in prolonging OS regardless of disease extent.
Abstract
Background/Aims: Elderly patients (≥ 80 years) with colorectal cancer (CRC) tend to avoid active treatment at the time of diagnosis despite of recent advances in treatment. The aim of this study was to determine treatment propensity of elderly patients aged ≥ 80 years with CRC in clinical practice and the impact of anticancer treatment on overall survival (OS). Methods: Medical charts of 152 elderly patients (aged ≥ 80 years) diagnosed with CRC between 1998 and 2012 were retrospectively reviewed. Patients’ clinical characteristics, treatment modalities received, and clinical outcome were analyzed. Results: Their median age was 82 years (range, 80 to 98). Of 152 patients, 148 were assessable for the extent of the disease. Eighty-two of 98 patients with localized disease and 28 of 50 patients with metastatic disease had received surgery or chemotherapy or both. Surgery was performed in 79 of 98 patients with localized disease and 15 of 50 patients with metastatic disease. Chemotherapy was administered in only 24 of 50 patients with metastatic disease. Patients who received anticancer treatment according to disease extent showed significantly longer OS compared to untreated patients (localized disease, 76.2 months vs. 15.4 months, p = 0.000; metastatic disease, 9.9 months vs. 2.6 months, p = 0.001). Along with anticancer treatment, favorable performance status (PS) was associated with longer OS in multivariate analysis of clinical outcome. Conclusions: Elderly patients aged ≥ 80 years with CRC tended to receive less treatment for metastatic disease. Nevertheless, anticancer treatment in patients with favorable PS was effective in prolonging OS regardless of disease extent.
참고문헌 (29)
- Siegel R, "Colorectal cancer statistics, 2014", CA Cancer J Clin, 64, pp.104~117 (2014)
- Sorbye H, "Age-dependent improvement in median and longterm survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer", Ann Oncol, 24, pp.2354~2360 (2013)
- Papamichael D, "Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013", Ann Oncol, 26, pp.463~476 (2015)
- Bojer AS, "Elderly patients with colorectal cancer are oncologically undertreated", Eur J Surg Oncol, 41, pp.421~425 (2015)
- Hardiman KM, "Disparities in the treatment of colon cancer in octogenarians", Am J Surg, 197, pp.624~628 (2009)
- Golfinopoulos V, "Treatment of colorectal cancer in the elderly: a review of the literature", Cancer Treat Rev, 32, pp.1~8 (2006)
- Nakamura T, "Feasibility and outcomes of surgical therapy in very elderly patients with colorectal cancer", Surg Laparosc Endosc Percutan Tech, 24, pp.85~88 (2014)
- Gurevitch AJ, "Outcome of right colectomy for cancer in octogenarians", J Gastrointest Surg, 13, pp.100~104 (2009)
- Yap R, "Colorectal cancer surgery in the very elderly: nonagenarians", Dis Colon Rectum, 59, pp.501~507 (2016)
- Iversen LH, "Age and colorectal cancer with focus on the elderly: trends in relative survival and initial treatment from a Danish population-based study", Dis Colon Rectum, 48, pp.1755~1763 (2005)
- Nascimbeni R, "The changing impact of age on colorectal cancer surgery: a trend analysis", Colorectal Dis, 11, pp.13~18 (2009)
- Kumar R, "A population-based study of metastatic colorectal cancer in individuals aged ≥ 80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer", Cancer, 119, pp.722~728 (2013)
- Doat S, "Elderly patients with colorectal cancer: treatment modalities and survival in France. National data from the ThInDiT cohort study", Eur J Cancer, 50, pp.1276~1283 (2014)
- McKibbin T, "Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting", Oncologist, 13, pp.876~885 (2008)
- Seal BS, "Systemic therapy for colorectal cancer: patterns of chemotherapy and biologic therapy use in nationally representative US claims database", BioDrugs, 28, pp.229~236 (2014)
- Douillard JY, "Multicenter phase III study of uracil", tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer, 2002, pp.20, 3605~3616
- Hoff PM, "Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study", J Clin Oncol, 19, pp.2282~2292 (2001)
- Feliu J, "Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study", J Clin Oncol, 23, pp.3104~3111 (2005)
- Kroep JR, "Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer: TLC study", J Geriatr Oncol, 6, pp.307~315 (2015)
- Sanoff HK, "How we treat metastatic colon cancer in older adults", J Geriatr Oncol, 4, pp.295~301 (2013)
- Bradley CJ, "Trends in the treatment of metastatic colon and rectal cancer in elderly patients", Med Care, 54, pp.490~497 (2016)
- Aparicio T, "Randomized phase III trial in elderly patients comparing LV5FU2with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02)", Ann Oncol, 27, pp.121~127 (2016)
- Kawakami K, "Patients’self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis", Patient Prefer Adherence, 9, pp.561~567 (2015)
- Seal BS, "Factors associated with adherence rates for oral and intravenous anticancer therapy in commercially insured patients with metastatic colon cancer", J Manag Care Spec Pharm, 22, pp.227~235 (2016)
- Ohnishi T, "Successful low-dose TS-1 administration in an elderly colon cancer patient with liver metastasis", Gan To Kagaku Ryoho, 34, pp.623~625 (2007)
- 정윤화, "Metronomic chemotherapy with capecitabine for metastatic colorectal cancer in very elderly patients", The Korean Journal of Internal Medicine, 32(5), pp.926~929 (2017), 대한내과학회[DOI]
- Romiti A, "Continuous, lowdose capecitabine for patients with recurrent colorectal cancer", Med Oncol, 32, pp.54~ (2015)
- Rosati G, "A review and assessment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer", J Geriatr Oncol, 7, pp.134~141 (2016)
- Sclafani F, "Bevacizumab in elderly patients with metastatic colorectal cancer", J Geriatr Oncol, 5, pp.78~88 (2014)